Sphingosine 1-phosphate receptor agonists attenuate relapsing–remitting experimental autoimmune encephalitis in SJL mice

[1]  R. Proia,et al.  Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[2]  N. Gray,et al.  Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate* , 2004, Journal of Biological Chemistry.

[3]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[4]  E. Goetzl,et al.  The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  K. Claffey,et al.  Phosphorylation and Action of the Immunomodulator FTY720 Inhibits Vascular Endothelial Cell Growth Factor-induced Vascular Permeability* , 2003, Journal of Biological Chemistry.

[6]  M. Forrest,et al.  Sphingosine-1-Phosphate Receptor Agonism Impairs the Efficiency of the Local Immune Response by Altering Trafficking of Naive and Antigen-Activated CD4+ T Cells , 2003, The Journal of Immunology.

[7]  H. Amemiya,et al.  Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment , 2003, Journal of Pharmacology and Experimental Therapeutics.

[8]  V. Ling,et al.  Local delivery of granulocyte macrophage colony-stimulating factor by retrovirally transduced antigen-specific T cells leads to severe, chronic experimental autoimmune encephalomyelitis in mice , 2002, Neuroscience Letters.

[9]  J. Dwyer,et al.  Estrogen inhibition of EAE involves effects on dendritic cell function , 2002, Journal of neuroscience research.

[10]  D. Bourdette,et al.  Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis , 2002, Journal of Neuroimmunology.

[11]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[12]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[13]  B. Trapp,et al.  Axon Loss in the Spinal Cord Determines Permanent Neurological Disability in an Animal Model of Multiple Sclerosis , 2002, Journal of neuropathology and experimental neurology.

[14]  J. McQualter,et al.  Granulocyte Macrophage Colony-Stimulating Factor A New Putative Therapeutic Target in Multiple Sclerosis , 2001 .

[15]  V. Brinkmann,et al.  FTY720: altered lymphocyte traffic results in allograft protection. , 2001, Transplantation.

[16]  V. Brinkmann,et al.  FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. , 2001, Transplantation proceedings.

[17]  T. Imayoshi,et al.  Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats , 2000, Inflammation Research.

[18]  S. Enosawa,et al.  Evidence that FTY720 induces T cell apoptosis in vivo. , 2000, Immunopharmacology.

[19]  R. Zinkernagel,et al.  FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory1 , 2000, The Journal of Immunology.

[20]  L. Feng,et al.  FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. , 2000, Trends in pharmacological sciences.

[21]  J. Bronstein,et al.  Oligodendrocyte-specific protein peptides induce experimental autoimmune encephalomyelitis in SJL/J mice. , 1999, Journal of immunology.

[22]  B D Trapp,et al.  Axonal pathology in multiple sclerosis: relationship to neurologic disability. , 1999, Current opinion in neurology.

[23]  E. Goetzl,et al.  Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1‐phosphate , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  S. Suzuki,et al.  Prevention of experimentally induced autoimmune type I diabetes in rats by the new immunosuppressive reagent FTY720. , 1998, Transplantation proceedings.

[25]  K. Sugahara,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. , 1998, Journal of immunology.

[26]  H. Kataoka,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. , 1998, Journal of immunology.

[27]  S. Enosawa,et al.  The in vivo induction of lymphocyte apoptosis in MRL‐lpr/lpr mice treated with FTY720 , 1997, Clinical and experimental immunology.

[28]  S. Enosawa,et al.  A new immunosuppressant, FTY720, induces bcl‐2‐associated apoptotic cell death in human lymphocytes , 1996, Immunology.

[29]  Y. Yanagawa,et al.  FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. , 1996, Transplantation proceedings.

[30]  K. Chiba,et al.  FTY720, a novel immunosuppressant, possessing unique mechanisms. IV. Prevention of graft versus host reactions in rats. , 1996, Transplantation proceedings.

[31]  S. Enosawa,et al.  A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. , 1996, Transplantation.

[32]  S. Miller,et al.  Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis , 1995, The Journal of experimental medicine.

[33]  S. Miller,et al.  Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein , 1992, Journal of Neuroimmunology.

[34]  R. Sobel,et al.  Acute Experimental Allergic Encephalomyelitis in SJL/J Mice Induced by a Synthetic Peptide of Myelin Proteolipid Protein , 1990, Journal of neuropathology and experimental neurology.

[35]  W. Sewell,et al.  Inhibition of lymphocyte circulation in mice by pertussis toxin , 1989, Immunology and cell biology.

[36]  A. Cooke,et al.  Immunological defects in SJL mice. , 1986, Immunology.

[37]  D. McFarlin,et al.  Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[38]  J. Weiner,et al.  Lysophospholipid receptors. , 2001, Annual review of pharmacology and toxicology.

[39]  J. Chun Lysophospholipid receptors: implications for neural signaling. , 1999, Critical reviews in neurobiology.

[40]  ichard,et al.  AXONAL TRANSECTION IN THE LESIONS OF MULTIPLE SCLEROSIS , 1998 .

[41]  Journal of Neuroimmunology , 2022 .